Enhancing the Breadth and Efficacy of Therapeutic Vaccines for Breast Cancer
Abstract
Over the past year, we have optimized various systems for the identification of tumor-reactive T cells, and generated potentially tumor-reactive T cell clones from a number of patient samples. We have also optimized protocols for antigen identification and TCR repertoire analysis. We are hopeful that we are close to verifying there are several clones generated in recently screened patients (such as BC81 mentioned in this report). We are now beginning to optimize assays to test T cell killing of target cells. These include LDH release based cytotoxicity assay and live cell imaging. Once we have identified tumor reactive T cells, we will then examine their levels in patient tissue by the use of histology, TCR repertoire analysis, and archived tissue samples.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2014
- Accession Number
- ADA613787
Entities
People
- Peter P Lee